Long term progression-free survival in a patient with locally advanced prostate cancer under low dose intermittent androgen deprivation therapy with bicalutamide only - Abstract

Androgen deprivation is a common treatment option in patients with locally advanced or metastatic prostate cancer.

No case of long term treatment with an intermittent approach with only low dose bicalutamide (50 mg daily) has been described yet. We report a 60-year-old patient, initially presenting with a PSA elevation of 19.2 ng/mL in 1996. After diagnosis of well to moderately differentiated prostate cancer by transrectal biopsy, the patient underwent an open radical prostatectomy. Final diagnosis was adenocarcinoma of the prostate, classified as pT3a, pR1, pV0, and pL1. Adjuvant intermittent androgen deprivation therapy with flutamide 250 mg was applied, which was changed to bicalutamide 50 mg once daily when it became available in 2001. Six on-phases were performed and PSA values never exceeded 20 ng/mL. The patient did not experience any serious side effects. To date, there are no clinical or radiological signs of progression. Current PSA value is 3.5 ng/mL.

Written by:
Latz S, Fisang C, Ebert W, Orth S, Engehausen DG, Müller SC, Anding R.   Are you the author?
Department of Urology, University Hospital Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, Germany; Department of Urology, Kreiskrankenhaus Luedenscheid, Paulmannshöher Straße 14, 58515 Luedenscheid, Germany; Department of Urology, Klinikum-Westfalen GmbH, Am Knappschaftskrankenhaus 1, 44309 Dortmund, Germany; Department of Urology, University Hospital Erlangen, Krankenhausstraße 12, 91054 Erlangen, Germany; Sinntal Hospital Bad Brückenau, Hospital of the Deutsche Rentenversicherung Nordbayern, Wernarzer Straße 12, 97769 Bad Brückenau, Germany.

Reference: Case Rep Urol. 2015;2015:928787.
doi: 10.1155/2015/928787

PubMed Abstract
PMID: 25883827

UroToday.com Prostate Cancer Section


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.